DE60113683D1 - Radiotherapy - Google Patents

Radiotherapy

Info

Publication number
DE60113683D1
DE60113683D1 DE60113683T DE60113683T DE60113683D1 DE 60113683 D1 DE60113683 D1 DE 60113683D1 DE 60113683 T DE60113683 T DE 60113683T DE 60113683 T DE60113683 T DE 60113683T DE 60113683 D1 DE60113683 D1 DE 60113683D1
Authority
DE
Germany
Prior art keywords
bone
tumors
human
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60113683T
Other languages
English (en)
Other versions
DE60113683T2 (de
Inventor
Roy H Larsen
Gjermund Henriksen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AS
Original Assignee
Algeta ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta ASA filed Critical Algeta ASA
Publication of DE60113683D1 publication Critical patent/DE60113683D1/de
Application granted granted Critical
Publication of DE60113683T2 publication Critical patent/DE60113683T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DE60113683T 2000-07-04 2001-07-04 Radiotherapy Expired - Lifetime DE60113683T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20003457 2000-07-04
NO20003457A NO313180B1 (no) 2000-07-04 2000-07-04 Bensökende alfapartikkel emitterende radiofarmasöytika
PCT/GB2001/002996 WO2002005859A2 (en) 2000-07-04 2001-07-04 Radiotherapy

Publications (2)

Publication Number Publication Date
DE60113683D1 true DE60113683D1 (en) 2006-02-09
DE60113683T2 DE60113683T2 (de) 2006-07-06

Family

ID=19911348

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60113683T Expired - Lifetime DE60113683T2 (de) 2000-07-04 2001-07-04 Radiotherapy

Country Status (15)

Country Link
US (2) US7056275B2 (de)
EP (1) EP1296722B1 (de)
JP (1) JP5219325B2 (de)
KR (1) KR100892002B1 (de)
AT (1) ATE305313T1 (de)
AU (2) AU2001267734B2 (de)
CA (1) CA2413736C (de)
CZ (1) CZ299087B6 (de)
DE (1) DE60113683T2 (de)
DK (1) DK1296722T3 (de)
EA (1) EA004899B1 (de)
ES (1) ES2250419T3 (de)
NO (1) NO313180B1 (de)
PL (1) PL206209B1 (de)
WO (1) WO2002005859A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
EP1227849A2 (de) * 2000-02-25 2002-08-07 Dangshe Ma Aktinium-225 komplexe und konjugate zur radioimmuntherapie
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
NZ543044A (en) * 2003-04-15 2010-04-30 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
EA020542B1 (ru) * 2004-02-20 2014-12-30 Алгета Ас Альфа-излучающие частицы гидроксиапатита
EP1763372B1 (de) * 2004-06-25 2016-11-30 The European Union, represented by the European Commission Radionuklide zur medizinischer anwendung
LU91085B1 (en) * 2004-06-25 2005-12-27 European Community Radionuclides for medical use.
US7794691B2 (en) 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
US8557601B2 (en) 2006-07-10 2013-10-15 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
FR2913970B1 (fr) * 2007-03-19 2009-06-12 Cogema Production de thorium 228 a partir d'un sel de thorium naturel
US20080249398A1 (en) * 2007-04-09 2008-10-09 Harder George Fred Hybrid Source Containing Multi-Radionuclides for Use in Radiation Therapy
EP2470513B1 (de) 2009-08-24 2014-10-08 Lumiphore, Inc. Makrozyklische hopo-chelatoren
WO2011079291A1 (en) * 2009-12-24 2011-06-30 Lumiphore, Inc. Radiopharmaceutical complexes
US9202602B2 (en) * 2010-02-10 2015-12-01 Uchicago Argonne, Llc Production of isotopes using high power proton beams
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201314718D0 (en) * 2013-08-16 2013-10-02 Algeta As Quantification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
EP3432936A1 (de) 2016-03-24 2019-01-30 Bayer Pharma Aktiengesellschaft Radiopharmazeutische komplexe
AU2017277463A1 (en) 2016-06-10 2019-01-03 Bayer As Radio-pharmaceutical complexes
RU2763750C2 (ru) 2017-05-11 2022-01-10 Альфа Тау Медикал Лтд. Полимерные покрытия для брахитерапевтических устройств
WO2019193464A1 (en) 2018-04-02 2019-10-10 Alpha Tau Medical Ltd. Controlled release of radionuclides
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
US20220152228A1 (en) * 2019-03-01 2022-05-19 Washington University Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата
IL303002A (en) 2020-12-16 2023-07-01 Alpha Tau Medical Ltd Radiotherapy by diffuse alpha emitters with increased beta therapy
KR102545315B1 (ko) 2021-01-05 2023-06-20 한국과학기술원 의료용 방사성 동위원소의 생산 방법 및 시스템

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2329147A (en) * 1938-05-07 1943-09-07 Rare Chemicals Inc Stabilized metal sol and method of preparing same
US4560548A (en) * 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5192526A (en) * 1989-05-02 1993-03-09 Mallinckrodt Medical, Inc. Kit for preparation of rhenium therapeutic agents for bone cancer without purification
LU87684A1 (de) * 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
JP2003501488A (ja) * 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
EP1227849A2 (de) * 2000-02-25 2002-08-07 Dangshe Ma Aktinium-225 komplexe und konjugate zur radioimmuntherapie
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
GB0213261D0 (en) 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060228297A1 (en) 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy

Also Published As

Publication number Publication date
ATE305313T1 (de) 2005-10-15
KR100892002B1 (ko) 2009-04-07
EA200201258A1 (ru) 2003-06-26
AU6773401A (en) 2002-01-30
EP1296722A2 (de) 2003-04-02
PL366070A1 (en) 2005-01-24
WO2002005859A2 (en) 2002-01-24
EA004899B1 (ru) 2004-08-26
DK1296722T3 (da) 2006-02-13
PL206209B1 (pl) 2010-07-30
NO313180B1 (no) 2002-08-26
WO2002005859A3 (en) 2002-09-06
JP5219325B2 (ja) 2013-06-26
NO20003457L (no) 2002-01-07
ES2250419T3 (es) 2006-04-16
CA2413736C (en) 2009-08-18
EP1296722B1 (de) 2005-09-28
NO20003457D0 (no) 2000-07-04
KR20030029100A (ko) 2003-04-11
AU2001267734B2 (en) 2005-09-01
US7056275B2 (en) 2006-06-06
DE60113683T2 (de) 2006-07-06
CA2413736A1 (en) 2002-01-24
US7335154B2 (en) 2008-02-26
US20030166989A1 (en) 2003-09-04
US20060135842A1 (en) 2006-06-22
CZ299087B6 (cs) 2008-04-23
JP2004503331A (ja) 2004-02-05

Similar Documents

Publication Publication Date Title
DE60113683D1 (en) Radiotherapy
TR200102707T2 (tr) AĞrì hafifletme, kemik kanseri terapisi ve kemik yzeyinin saĞlìklì tutulmasì i‡in kire‡lenmiç hedef dokulara y”nelik radyum-223 hazìrlanmasì ve kullanìmì.
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
PT1472541E (pt) Agentes de imagiologia e métodos de imagiologia de naaladase de psma
PT1429792E (pt) Composto de estrôncio para o tratamento de dor nos tecidos moles subcutâneos
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
DE60324448D1 (de) Brachytherapievorrichtung
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
TR200101225T2 (tr) Brakiterapi için ürünler ve yöntemler.
DE69532810D1 (de) Intravenöse alendronatformulierungen
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
AU3842989A (en) Conjugates for bone imaging and bone cancer therapy
Levendag et al. A new applicator design for endocavitary brachytherapy of cancer in the nasopharynx
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
MXPA05006722A (es) Metodo para tratamiento de pacientes con exposicion a radiacion.
NO20064232L (no) Alfa.emitterende hydroksyapatittparikler
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
EP0904094A4 (de) Behandlung von knochenleiden mit adrenomedullin
UA11383U (uk) Спосіб терапії хворих на рак щитовидної залози з множинними метастазами в скелет
UA42427A (uk) Спосіб корекції целюліту та/або локальних жирових відкладень
IT1312106B1 (it) Suola o soletta per calzature,particolarmente per la terapia del corpo umano mediante campi magnetici

Legal Events

Date Code Title Description
8364 No opposition during term of opposition